Generic Drug Review June 2019
Biosimilars: Not Simply Generics
With the entry of biosimilars into the U.S. market, it is important for pharmacists to understand these products and how they differ from generic medications.
FDA Update on Recent Voluntary ARB Drug Recalls
Recent voluntary recalls of certain angiotensin II receptor blockers have heightened scrutiny of the non-U.S. manufacturing of drugs marketed in the U.S. and of FDA oversight of the process.
Continuing Education
$7.95 Per CE Exam or $69 for 12 Lessons
-
• April 2026 • 2.00 Credits
Managing HIV Coinfections and Complications
-
Pain Management • March 2026 • 2.00 Credits
Updated Guidance for Opioid Use in Pain Management
-
Cardiovascular • February 2026 • 2.00 Credits
Managing Modifiable Risk Factors in Chronic Coronary Disease
Copyright © 2000 - 2024 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.